NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free MIRM Stock Alerts $25.98 -0.79 (-2.95%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$25.64▼$26.9450-Day Range$25.98▼$29.9352-Week Range$21.83▼$35.56Volume789,916 shsAverage Volume610,994 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$52.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mirum Pharmaceuticals alerts: Email Address Mirum Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside100.6% Upside$52.11 Price TargetShort InterestBearish16.43% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.87Based on 28 Articles This WeekInsider TradingSelling Shares$248,102 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.16) to $0.79 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector189th out of 947 stocksPharmaceutical Preparations Industry84th out of 435 stocks 3.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.11, Mirum Pharmaceuticals has a forecasted upside of 100.6% from its current price of $25.98.Amount of Analyst CoverageMirum Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.43% of the outstanding shares of Mirum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 1.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 3.3 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest11 people have searched for MIRM on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold 380.82% more of their company's stock than they have bought. Specifically, they have bought $51,600.00 in company stock and sold $248,102.00 in company stock.Percentage Held by Insiders24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.16) to $0.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 6.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Given New $43.00 Price Target at SVB LeerinkMarch 18, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Mirum PharmaceuticalsMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 18, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Issued By Leerink PartnrsMarch 17, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 3.9%March 16, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $27.77March 15, 2024 | ca.finance.yahoo.comMIRM Mar 2024 40.000 callMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Promising Pipeline DevelopmentsMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 15, 2024 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from AnalystsMarch 14, 2024 | msn.comFDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion StrategyMarch 14, 2024 | marketwatch.comMirum Pharmaceuticals Gets Additional FDA Approval for LivmarliMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue OutlookMarch 14, 2024 | msn.com3 Best Stocks to Buy Now, 3/14/2024, According to Top AnalystsMarch 14, 2024 | msn.comMirum gains as FDA accepts label expansion of liver disease drugMarch 13, 2024 | reuters.comUS FDA approves expanded use of Mirum's liver disease drugMarch 13, 2024 | finance.yahoo.comMirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisMarch 13, 2024 | businesswire.comMirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisMarch 8, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | seekingalpha.comMirum Pharmaceuticals: Advancing On Several Key FrontsMarch 1, 2024 | seekingalpha.comMirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comCritical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To KnowFebruary 29, 2024 | stockhouse.comHepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLIFebruary 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART)February 29, 2024 | finance.yahoo.comHepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLIFebruary 28, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ...February 28, 2024 | seekingalpha.comMirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call PresentationSee More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees249Year FoundedN/APrice Target and Rating Average Stock Price Target$52.11 High Stock Price Target$72.00 Low Stock Price Target$35.00 Potential Upside/Downside+100.6%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,900,000.00 Net Margins-86.33% Pretax Margin-112.82% Return on Equity-74.95% Return on Assets-25.66% Debt Debt-to-Equity Ratio1.14 Current Ratio5.20 Quick Ratio4.91 Sales & Book Value Annual Sales$186.37 million Price / Sales6.50 Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book6.75Miscellaneous Outstanding Shares46,610,000Free Float35,399,000Market Cap$1.21 billion OptionableOptionable Beta1.16 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 45)CEO & Director Comp: $1.09MMr. Peter Radovich M.B.A. (Age 46)Ph.D., COO & President Comp: $732.15kDr. Pamela Vig Ph.D. (Age 53)Chief Scientific Officer & Head of Research Comp: $678.2kMs. Lara Longpre MBA (Age 54)MSC, Chief Development Officer Comp: $678.2kMr. Eric H. Bjerkholt M.B.A. (Age 64)Chief Financial Officer Andrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 56)Senior Vice President of Human Resources Dr. Ian Clements Ph.D. (Age 55)Consultant Comp: $649.1kMs. Vinita P. KumarSenior vice President of QualityMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDDay One BiopharmaceuticalsNASDAQ:DAWNDeciphera PharmaceuticalsNASDAQ:DCPHVerona PharmaNASDAQ:VRNAImmunomeNASDAQ:IMNMView All CompetitorsInsiders & InstitutionsEric BjerkholtBought 2,000 shares on 3/18/2024Total: $51,600.00 ($25.80/share)Vanguard Group Inc.Bought 782,901 shares on 3/11/2024Ownership: 5.313%Goldman Sachs Group Inc.Bought 215,542 shares on 3/1/2024Ownership: 0.979%Perceptive Advisors LLCSold 137,100 shares on 2/26/2024Ownership: 1.148%Virtu Financial LLCSold 1,561 shares on 2/26/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions MIRM Stock Analysis - Frequently Asked Questions Should I buy or sell Mirum Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks. What is Mirum Pharmaceuticals' stock price target for 2024? 8 equities research analysts have issued 1-year target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $35.00 to $72.00. On average, they predict the company's share price to reach $52.11 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts. How have MIRM shares performed in 2024? Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of the year. Since then, MIRM shares have decreased by 12.0% and is now trading at $25.98. View the best growth stocks for 2024 here. When is Mirum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MIRM earnings forecast. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings data on Monday, November, 15th. The company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.08. The business had revenue of $5 million for the quarter, compared to analysts' expectations of $5 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 74.95%. During the same period in the prior year, the company posted ($0.86) EPS. What ETFs hold Mirum Pharmaceuticals' stock? ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP). What guidance has Mirum Pharmaceuticals issued on next quarter's earnings? Mirum Pharmaceuticals issued an update on its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $186.0 million-$188.0 million, compared to the consensus revenue estimate of $185.4 million. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX). When did Mirum Pharmaceuticals IPO? (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (13.93%), Eventide Asset Management LLC (5.71%), Vanguard Group Inc. (5.31%), Vanguard Group Inc. (5.31%), Cadian Capital Management LP (4.15%) and Price T Rowe Associates Inc. MD (2.50%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRM) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.